A circular RNA protects the heart from pathological hypertrophy and heart failure by targeting miR-223

被引:779
|
作者
Wang, Kun [1 ]
Long, Bo [2 ,3 ]
Liu, Fang [4 ]
Wang, Jian-Xun [1 ]
Liu, Cui-Yun [1 ]
Zhao, Bing [1 ]
Zhou, Lu-Yu [1 ]
Sun, Teng [1 ]
Wang, Man [1 ]
Yu, Tao [1 ]
Gong, Ying [1 ]
Liu, Jia [1 ]
Dong, Yan-Han [1 ]
Li, Na [1 ]
Li, Pei-Feng [1 ]
机构
[1] Qingdao Univ, Inst Translat Med, Coll Med, Ctr Dev Cardiol, Qingdao 266021, Peoples R China
[2] Chinese Acad Med Sci, Peking Union Med Coll Hosp, Cent Res Lab, Lab Mol Med, Beijing 100730, Peoples R China
[3] Peking Union Med Coll, Beijing 100730, Peoples R China
[4] Guilin Med Univ, Dept Anat, Coll Basic Med, Guilin 541004, Peoples R China
基金
北京市自然科学基金; 中国国家自然科学基金;
关键词
Circular RNA; HRCR; Cardiac hypertrophy; Heart failure; CASPASE RECRUITMENT DOMAIN; MUSCLE-SPECIFIC MICRORNA; CARDIAC-HYPERTROPHY; APOPTOSIS REPRESSOR; CARDIOMYOCYTE HYPERTROPHY; CELL PROLIFERATION; SKELETAL-MUSCLE; DIFFERENTIATION; OVEREXPRESSION; TRANSCRIPTS;
D O I
10.1093/eurheartj/ehv713
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Our present study reveals a novel cardiac hypertrophic regulating model that is composed of circRNA, miR-223, and ARC. Modulation of their levels may provide a new approach for tackling cardiac hypertrophy and heart failure. Our present work advances our understanding about the role of circRNAs and miRNAs in cardiac hypertrophy and heart failure. Circular RNA may represent a potential new therapeutic strategy to attenuate the pathogenesis of cardiac diseases.Sustained cardiac hypertrophy accompanied by maladaptive cardiac remodelling represents an early event in the clinical course leading to heart failure. Maladaptive hypertrophy is considered to be a therapeutic target for heart failure. However, the molecular mechanisms that regulate cardiac hypertrophy are largely unknown. Here we show that a circular RNA (circRNA), which we term heart-related circRNA (HRCR), acts as an endogenous miR-223 sponge to inhibit cardiac hypertrophy and heart failure. miR-223 transgenic mice developed cardiac hypertrophy and heart failure, whereas miR-223-deficient mice were protected from hypertrophic stimuli, indicating that miR-223 acts as a positive regulator of cardiac hypertrophy. We identified ARC as a miR-223 downstream target to mediate the function of miR-223 in cardiac hypertrophy. Apoptosis repressor with CARD domain transgenic mice showed reduced hypertrophic responses. Further, we found that a circRNA HRCR functions as an endogenous miR-223 sponge to sequester and inhibit miR-223 activity, which resulted in the increase of ARC expression. Heart-related circRNA directly bound to miR-223 in cytoplasm and enforced expression of HRCR in cardiomyocytes and in mice both exhibited attenuated hypertrophic responses. These findings disclose a novel regulatory pathway that is composed of HRCR, miR-223, and ARC. Modulation of their levels provides an attractive therapeutic target for the treatment of cardiac hypertrophy and heart failure.
引用
收藏
页码:2602 / U24
页数:11
相关论文
共 50 条
  • [1] A long noncoding RNA protects the heart from pathological hypertrophy
    Han, Pei
    Li, Wei
    Lin, Chiou-Hong
    Yang, Jin
    Shang, Ching
    Nurnberg, Sylvia T.
    Jin, Kevin Kai
    Xu, Weihong
    Lin, Chieh-Yu
    Lin, Chien-Jung
    Xiong, Yiqin
    Chien, Huan-Chieh
    Zhou, Bin
    Ashley, Euan
    Bernstein, Daniel
    Chen, Peng-Sheng
    Chen, Huei-Sheng Vincent
    Quertermous, Thomas
    Chang, Ching-Pin
    NATURE, 2014, 514 (7520) : 102 - +
  • [2] Loss of MicroRNA-155 Protects the Heart From Pathological Cardiac Hypertrophy
    Seok, Hee Young
    Chen, Jinghai
    Kataoka, Masaharu
    Huang, Zhan-Peng
    Ding, Jian
    Yan, Jinglu
    Hu, Xiaoyun
    Wang, Da-Zhi
    CIRCULATION RESEARCH, 2014, 114 (10) : 1585 - 1595
  • [3] The Role of PPARs in Pathological Cardiac Hypertrophy and Heart Failure
    Liao, Hai-Han
    Jia, Xu-Hui
    Liu, Huang-Jun
    Yang, Zheng
    Tang, Qi-Zhu
    CURRENT PHARMACEUTICAL DESIGN, 2017, 23 (11) : 1677 - 1686
  • [4] MiR-590-5p inhibits pathological hypertrophy mediated heart failure by targeting RTN4
    Fan, Ping
    Zhang, Likun
    Cheng, Tianyu
    Wang, Jing
    Zhou, Junyun
    Zhao, Li
    Hua, Cuie
    Xia, Quan
    JOURNAL OF MOLECULAR HISTOLOGY, 2021, 52 (05) : 955 - 964
  • [5] miR-222 inhibits pathological cardiac hypertrophy and heart failure
    Liu, Xiaojun
    Li, Haobo
    Hastings, Margaret H.
    Xiao, Chunyang
    Damilano, Federico
    Platt, Colin
    Lerchenmueller, Carolin
    Zhu, Han
    Wei, Xin Paul
    Yeri, Ashish
    Most, Patrick
    Rosenzweig, Anthony
    CARDIOVASCULAR RESEARCH, 2024, 120 (03) : 262 - 272
  • [6] Ablation of lncRNA Miat attenuates pathological hypertrophy and heart failure
    Yang, Liu
    Deng, Jianxin
    Ma, Wenxia
    Qiao, Aijun
    Xu, Shiyue
    Yu, Yang
    Boriboun, Chan
    Kang, Xiang
    Han, Dunzheng
    Ernst, Patrick
    Zhou, Lufang
    Shi, Jiawei
    Zhang, Eric
    Li, Tao-Sheng
    Qiu, Hongyu
    Nakagawa, Shinichi
    Blackshaw, Seth
    Zhang, Jianyi
    Qin, Gangjian
    THERANOSTICS, 2021, 11 (16): : 7995 - 8007
  • [7] AAV-mediated expression of NFAT decoy oligonucleotides protects from cardiac hypertrophy and heart failure
    Remes, Anca
    Wagner, Andreas H.
    Schmiedel, Nesrin
    Heckmann, Markus
    Ruf, Theresa
    Ding, Lin
    Jungmann, Andreas
    Senger, Frauke
    Katus, Hugo A.
    Ullrich, Nina D.
    Frey, Norbert
    Hecker, Markus
    Mueller, Oliver J.
    BASIC RESEARCH IN CARDIOLOGY, 2021, 116 (01)
  • [8] AAV-mediated expression of NFAT decoy oligonucleotides protects from cardiac hypertrophy and heart failure
    Anca Remes
    Andreas H. Wagner
    Nesrin Schmiedel
    Markus Heckmann
    Theresa Ruf
    Lin Ding
    Andreas Jungmann
    Frauke Senger
    Hugo A. Katus
    Nina D. Ullrich
    Norbert Frey
    Markus Hecker
    Oliver J. Müller
    Basic Research in Cardiology, 2021, 116
  • [9] The long noncoding RNA XIST protects cardiomyocyte hypertrophy by targeting miR-330-3p
    Chen, Yuewu
    Liu, Xianxia
    Chen, Lei
    Chen, Weiwei
    Zhang, Yuansheng
    Chen, Jiaxian
    Wu, Xuezheng
    Zhao, Yong
    Wu, Xiaoyan
    Sun, Guowei
    BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 2018, 505 (03) : 807 - 815
  • [10] Cardiac Hypertrophy: From Pathophysiological Mechanisms to Heart Failure Development
    Caturano, Alfredo
    Vetrano, Erica
    Galiero, Raffaele
    Salvatore, Teresa
    Docimo, Giovanni
    Epifani, Raffaella
    Alfano, Maria
    Sardu, Celestino
    Marfella, Raffaele
    Rinaldi, Luca
    Sasso, Ferdinando Carlo
    REVIEWS IN CARDIOVASCULAR MEDICINE, 2022, 23 (05)